CELYAD SA/ADR (NASDAQ:CYAD) has been assigned a consensus rating of “Buy” from the seven research firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $44.20.
CYAD has been the subject of a number of recent analyst reports. William Blair reaffirmed a “buy” rating on shares of CELYAD SA/ADR in a research note on Tuesday, December 4th. HC Wainwright reiterated a “buy” rating and set a $46.00 price objective on shares of CELYAD SA/ADR in a research note on Wednesday, November 21st. Zacks Investment Research upgraded shares of CELYAD SA/ADR from a “hold” rating to a “buy” rating and set a $31.00 price objective for the company in a research note on Thursday, November 15th. Finally, Piper Jaffray Companies reduced their price objective on shares of CELYAD SA/ADR to $51.00 and set an “overweight” rating for the company in a research note on Monday, November 12th.
CYAD traded up $0.10 during trading on Friday, hitting $22.59. The company’s stock had a trading volume of 22,742 shares, compared to its average volume of 9,136. CELYAD SA/ADR has a one year low of $15.36 and a one year high of $48.20. The company has a market capitalization of $223.02 million, a PE ratio of -6.38 and a beta of 1.77.
About CELYAD SA/ADR
Celyad SA, a clinical-stage biopharmaceutical company, focuses on the development of CAR-T cell-based therapies. The company utilizes its expertise in cell engineering to target cancer. Its CAR-T cell platform has the potential to treats a range of solid and hematologic tumors. The company's lead drug product candidate, CYAD-01 (CAR-T NKG2D), has been evaluated in a Phase I clinical trial to assess the safety and clinical activity of multiple administrations of autologous CYAD-01 cells in seven refractory cancers, including five solid tumors, such as colorectal, ovarian, bladder, triple-negative breast, and pancreatic cancers; and two hematological tumors comprising acute myeloid leukemia and multiple myeloma.
Recommended Story: Risk Tolerance and Your Investment Decisions
Receive News & Ratings for CELYAD SA/ADR Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CELYAD SA/ADR and related companies with MarketBeat.com's FREE daily email newsletter.